WALLIS MOLCHEN to Adult
This is a "connection" page, showing publications WALLIS MOLCHEN has written about Adult.
Connection Strength
0.057
-
Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial. Hepatology. 2011 Nov; 54(5):1527-37.
Score: 0.011
-
A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology. 2011 Jul; 141(1):141-9.
Score: 0.011
-
Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut. 2010 Oct; 59(10):1401-9.
Score: 0.010
-
Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis. Clin Gastroenterol Hepatol. 2009 Feb; 7(2):219-26.
Score: 0.009
-
Serum vitamin D levels are not predictive of the progression of chronic liver disease in hepatitis C patients with advanced fibrosis. PLoS One. 2012; 7(2):e27144.
Score: 0.006
-
Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology. 2011 Apr; 53(4):1100-8.
Score: 0.005
-
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2009 Jan; 136(1):138-48.
Score: 0.004